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ABSTRACT
Epilepsy is a disorder characterized by the occurrence of seizures, which are periods
of abnormally excessive synchronous neuronal activity in the brain. Affecting over 70
million people worldwide, many of whom do not respond to pharmacotherapy, there is a
need for novel anticonvulsant compound discovery. Diaminodiphenyl compounds, a class
of compounds shown to present anticonvulsive effects in vivo have been purported to
exert their effects on the N-methyl-D-aspartate receptor (NMDAr); an excitatory,
ionotropic receptor that is a key player in the functions of the glutamatergic system. The
glutamatergic system is vital in the promotion of synaptic plasticity and has been
implicated in a myriad of mental health issues, including epilepsy.
We hypothesize that diaminodiphenyl compounds interact with NMDAr at an
allosteric binding site on the NR2 subunit which is activated by the agonist glutamate.
This project is intended to characterize the diaminodiphenyl binding interactions with
NMDAr, elucidate a structure activity relationship between diaminodiphenyl compounds
and NMDAr and create novel diaminodiphenyl compounds employing rational drug
design to improve the therapeutic index of the compounds.
The data presented in the following manuscripts characterizes a novel binding motif
between diaminodiphenyl compounds and NMDAr using computer based modeling
techniques. A structure activity relationship was derived by examining the anticonvulsant
effects of several different diaminodiphenyl compounds in animal models of epilepsy.
Employing the computationally derived binding motif and structure activity relationship,
several diaminodiphenyl derivatives have been designed in an effort to alleviate
metabolic toxicity and improve anticonvulsive potency.

Rational drug design targeting the described diaminodiphenyl binding site could
offer novel anticonvulsants which act through a novel mechanism on NMDAr.
Antagonism of NMDAr is not limited to epilepsy alone, NMDAr has been implicated in a
number of disease states and diaminodiphenyls could serve multiple indications such as:
neuropathy, mood disorders and post stroke outcomes.
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PREFACE
This dissertation was prepared according to the University of Rhode Island standards
for manuscript format. This dissertation is comprised of three manuscripts that have been
assembled in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at the University of Rhode Island.
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INTRODUCTION

Epilepsy is a complex disorder characterized by chronic periods of overactivity of
neurons in the cerebral cortex. A single seizure does not constitute the diagnosis of a
seizure disorder, as seizures can be caused by a multitude of neurological illnesses. In
order to be classified as epilepsy, there must be “recurrent unprovoked seizures”.1 The
systematic firing of neurons in the cerebral cortex is the basis by which normal brain
function and everyday life including speech, thought and movement occurs. A seizure is
the result of the loss of normal signaling patterns and overactive signaling in cerebral
neurons. However, not all seizures manifest clinically as a convulsive seizure which
stereotypes associate with epilepsy. The type of seizure is directly correlated to the region
of the brain affected by the neuronal overactivity. Convulsions are the result of the focal
point of the neuronal overactivity overlapping the motor neurons in the cerebral cortex. A
majority of seizures show no convulsive activity; in fact, epilepsy encompasses several
different types of seizures which have little in common aside from overactive
uncontrolled neuronal signaling in the cerebral cortex. The variability in clinical
manifestation as well as physiological underpinnings of the different seizure types
presents a challenge to doctors and neuroscientist in diagnosis, treatment, monitoring, and
drug development.
Repeated seizures can have a devastating effect on the brain. Glutamate is the primary
excitatory neurotransmitter in the brain. During seizure activity, the overexcitation of
cerebral neurons floods synapses and intracellular space with glutamate. Glutamate is a
primary ligand for NMDA, AMPA and kainite receptors, the ionotropic glutamate
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receptors in the central nervous system. Ionotropic receptors are responsible for the flow
of cations across the neuronal membrane, there by directly contributing to excitatory post
synaptic membrane potential and further seizure propagation. Overexcitiation of neurons
leading to the release of excess glutamate is also directly responsible for excitotoxicity, a
process by which neurons are excited to death leading to brain damage and
neurodegeneration.2,3 Epilepsy is estimated to affect almost 70 million people
worldwide1,2 and has a staggering economic cost. For example, the annual economic cost
to the United State in 1995 for 2.3 million cases then prevalent was estimated to be $12.5
billion and the life-time cost for the estimated 181,000 cases with an onset in that year
was estimated to be $11.1 billion.6 In addition, there are tragic non-economic costs to
patients and their families.
Since 1989, about 15 new anti-epileptic drugs (AEDs) have become available in the
clinic, providing patients and physicians with a number of treatment options.7,8
Nevertheless, a number of literature reviews of clinical studies have concluded that, even
with the availability of these new AEDs, the proportion of patients who are seizure free
after drug therapy amounts to only about 30%.8 In addition, the adverse effects of AEDs
can be serious enough to negatively affecting a patient’s quality of life, leading to issues
surrounding patient compliance with the medication dosing regimen.9 These side-effects
include dizziness, drowsiness, mental slowing, weight gain, metabolic acidosis,
nephrolithiasis, glaucoma, skin rash as well as movement and behavioral disorders,
among many others.9,10 The problems posed by the side-effects are compounded by the
requirement for multiple-drug therapy for adequate seizure control in many patients.11
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There remains a pressing need for the development additional AEDs with novel
mechanism of action that can provide patients and physicians with alternative treatment
options. Furthermore, it is clear that numerous and diverse underlying pathophysiological
mechanisms contribute to the epileptic syndrome. Therefore, access to a spectrum of
AEDs, with different modes of action, might facilitate the optimization of drug therapy to
suit the pharmacological and toxicological profiles of individual patients so as to improve
tolerability and long-term treatment success. The global AED market is a multibilliondollar enterprise that is still growing and the market for pharmaceutical treatment of
epilepsy generated $12 billion in 2008.12 Given this background, the development of an
AED with a novel mechanism of action is likely to be economically successful if it can
show superior efficacy, even in a subset of patients. While conventional antiepileptic
drugs have acted by blocking sodium channels or enhancing the function of γaminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain.11 The
newer drugs have more novel actions including binding to presynaptic vesicle proteins
and calcium channel subunits.
N-methyl-D-aspartate receptors (NMDARs) are important excitatory receptors and
play a key role in the pathophysiology of several neurological diseases, including
epilepsy, stroke, traumatic brain injury, dementia and schizophrenia which make it an
ideal candidate as an anticonvulsant drug target.13 The NMDAR is a hetero-tetrameric
cation channel formed as a complex between two NR1 and two NR2 subunits.14 Multiple
variants of NR1 and NR2 exist and can give rise to multiple NMDAR isoforms with
distinct brain distributions and functional properties. They are activated by the
neurotransmitter glutamate and the co-agonist glycine. NMDARs have a complex
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structure with regulatory binding sites for multiple agents including other cellular
proteins, Mg2+, and polyamines.
There is evidence to suggest that conventional antiepileptic drugs may inhibit
NMDAR function and that NMDAR antagonists could have unique utility in epilepsy
pharmacotherapy.15 NMDA receptor antagonists have been used as anesthetics and in
Alzheimer's but many of these ligands have poor efficacy or have failed clinical trials due
to narrow therapeutic indices and adverse effects. However, there is a large body of
evidence to suggest that ligands that more subtly modulate NMDARs hold tremendous
promise as therapeutic agents for multiple disorders including epilepsy, neuropathic pain,
substance abuse, and bipolar disorder and schizophrenia.13,14,15
Using rodent seizure models we have identified diaminodiphenyl (DADP) analogs as
novel pharmacophores with notable antiepileptic effects following systemic or oral
administration and these findings have been published.17 Based on our observations, we
have performed in silico modeling, in-vivo structure–activity relationship (SAR) studies,
and have observed functional modulation of mammalian NMDAR functionally expressed
in Xenopus oocytes, all of which have implicated NMDAR as a key molecular target in
the actions of these compounds.
Previous studies have suggested that other DADP-like compounds may modulate
NMDAR function18 which suggested a potential mechanism of action for the
anticonvulsant activity of the DADP analog, thiodianiline (TDA). Using NMDAR NR2a
crystal structure coordinates, 2A5S, from the Protein Data Base19 potential binding sites
were evaluated. The results of these studies revealed a large cavity into which DADP
compounds repeatedly bound with high affinity and with little variation between
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compounds (Fig 1). Furthermore, the model also discriminated between active and
inactive compounds as defined by previous in-vivo studies.
To investigate whether the interaction between NMDA receptors and TDA predicted
by in the in silico modeling studies could result in functional modulation of NMDAR
activity, we functionally expressed NMDAR in Xenopus oocytes by co-injecting cRNA
for the most ubiquitously expressed NMDA channel subunits NR1A and NR2B. 4-5 days
after cRNA injection, electrophysiological recordings using the two electrode voltage
clamp configuration were used to characterize NMDAR responses. Oocytes were
clamped at -70 mV and perfused with 1 µM glycine and 50 µM glutamate which resulted
robust positive inward currents only in oocytes injected with both channel subunits. Coapplication of TDA with glutamate inhibited the glutamate-elicited NMDAR
conductance (Fig 2). NMDAR inhibition was readily reversible upon TDA wash out.
Rational drug design may be an effective approach for producing potent targeted drug
therapies and alleviate know toxic mechanisms. In order to transition from inefficient
high throughput screening protocol to a systematic rational drug design protocol a well
defined binding pocket, key amino acids and binding interactions must be identified. By
combining a full range of methods, including flexible side chain models and homology
modeling, with the established electrophysiology based techniques, it is hypothesized that
the binding pocket and key interactions between DADPs and NMDAR can be elucidated.
NMDAR is a complex receptor whose dysfunction in noted in a variety of disorders.
This study proposes to characterize a novel binding site on NMDAR which may prove to
be a viable druggable target. The resulting data could be used to develop new lead
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compounds and provide viable treatment options for epilepsy and a variety of other
glutamate related disorders.
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Figure 1. Crystaline structure of NMDAr NR2 as reported by Furukawa, et al. with
diaminodiphenyl compounds overlayed in the proposed diaminodiphenyl
binding motif.
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Figure 2. NMDAr inhibition assay, in which diaminodiphenyl sulfide is capable of
antagonizing mammalian NMDAr expressed in Xenopus oocyte
reversibily in the presence of the agonists glycine and glutamate.
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Abstract
The N-methyl D-Aspartate receptor (NMDAr), a non-selective ion channel, has been
shown to interact with and be modulated by polyamines. Diaminodiphenyls have been
reported to elicit anticonvulsive effects by interacting with NMDAr. However, many
diaminodiphenyls have been reported to be toxic. in silico modeling of diaminodiphenyls
and their derivatives using mammalian NMDAr NR2a subunit crystal, 2A5S, has
provided evidence that diaminodiphenyls bind with favorable binding energy and may
modulate glutamate activation of NMDAr. The exact mechanism by which
diaminodiphenyls and their derivatives modulate NMDAr activity still needs to be
elucidated.

Introduction
The N-Methyl D-aspartate receptor (NMDAr), a ligand gated non-specific cation
channel, is essential to neuronal plasticity, chronic pain, and may also be involved in
seizure development 1. This tetrameric ion channel is composed of a dimer of dimers
made up of subunits NR1a-h, NR2a-d and NR3a-b 2. Subunit NR2 has been shown to
interact with and be activated by glutamate. The agonist binding site has been studied and
characterized at length. However, another class of molecules, polyamines, has been
reported to interact with NR2.
The interaction of NMDAr subunit NR2a-b with polyamines has been extensively
reported, however, there is little agreement on the binding interaction, effects or site of
interaction. According to a review by Mony, et al., the response of NMDAr to polyamine
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interaction is highly voltage dependant and has been characterized by three distinct
mechanisms; which include: increased affinity for glycine resulting in more rapid
receptor reset and decreased affinity for glutamate resulting in decreased NMDAr
activation 4,5. Most literature states that polyamine interactions with NMDAr occur at an
allosteric binding site eliciting the noted effects. The endogenous polyamine spermine
has been characterized in Xenopus oocytes using patch clamp analysis to monitor
NMDAr activation. The results of these studies suggest that spermine potentiates agonist
activation of NMDAr 3. In contrast, it is proposed that treatment of rats with
diaminodiphenyl compounds significantly reduced seizure in both MES and hippocampal
kindling models in vivo by modulating through an interation with NMDAr 6.
Diaminodiphenyl sulfide has been shown as a potent anticonvulsant. However, the
potential toxicity of any aromatic amine must always be addressed before a compound
could be investigated as an investigational API. Based on the toxic mechanism of aniline
it can be assumed that N-oxidation will lead to the production of a key toxic metabolite
which can be further metabolized leading to blood toxicity and DNA adduct formation 7
(Fig 1). In order to reduce the proposed toxic effects of diaminodiphenyl sulfide, rational
drug design must be used to eliminate the potential for the formation of the key hydroxyl
amine metabolite.
Methods
In Silico Ligands
Ligands were created using ChemBio3D Ultra 12. All ligands were drawn using
program defaults, and then the energy of each ligand was minimized using MM2 energy
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minimization function before being saved in a format suitable for docking in
AutoDock4.2. (Fig 2).
In Silico NMDA Model
Several crystal structures of NMDAr have been reported in the Protein Data Bank
(PDB).
Selection of the crystal structure 2A5S, deposited by Furukawa, et al. 2005, from
PDB was based on the energy scores and bond angle analysis provided by PDB.org. The
structure is composed of 284 amino acids isolated from rat and represents the core ligand
binding domain of NMDAr NR2a. The structure was co-crystallized with glutamate and
determined to a resolution of 1.7 angstrom using X-ray diffraction.
Using Accelrys Discovery Studio 3.1 all amino acid and charge corrections were
completed before the removal of the ligand and water molecules. The file was then
converted to MOL2, a suitable format for use in AutoDock 4.2. Further analysis of the
protein structure, using Discovery Studio 3.1, included determination of the ligand
binding site location. A cavity (Fig 3) was characterized and used to define the
coordinates of the grid box used in future docking experiments.

In Silico Docking to NMDA NR2a
Grid Box Selection
The grid box was initially centered on the ligand glutamate and further refined, using
the coordinates determined previously in Discovery Studio 3.1, in order to encompass the
cavity of the protein in which glutamate binding was characterized.
The grid was centered at (21.5, 21.4, 36.1) with dimensions of:
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Grid map x-dimension : 22.5 Angstroms
Grid map y-dimension : 22.5 Angstroms
Grid map z-dimension : 24.0 Angstroms

The gridbox was overlaid on the water-free ligand-free structure 2A5S produced in
Discovery Studio 3.1 and processed using default AutoGrid parameters in
AutoDockTools 4.2.
AutoDock Parameters
AutoDock parameters were held constant when docking each ligand with the
prepared NMDAr NR2a structure 2A5s. Each ligand was docked starting from a
computer generated seed site to the protein within the gridbox previously described.
Using default Lamarckian Algorithm settings set to default short run in AutoDock 4, the
energy was minimized. Optimum binding energy and ligand conformation was then
determined and recorded by AutoDock. (Table 1) This process was repeated 256 times
for each ligand and the data was compiled. The conformations are then grouped based on
similar location and orientation with a 2 angstrom deviation to the mean of the population
as the grouping criteria.

Results and Discussion
Diaminodiphenyl compounds appear to bind to NMDAr NR2A subunit in a specific
orientation, while hydrogen bonding with THR174 which may contribute to the reported
NMDAr effects in epilepsy.(Fig 4) The ligands evaluated addressed several key variables
which may affect the interactions between ligand and NMDAr; they were: linker element,
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linker substitution, linker length, N-substitution, aromatic substitution and aromaticity.
The diaminodiphenyl derivatives evaluated are rationally designed to prevent the toxic
metabolism of the diaminodiphenyls. These derivatives examine the effects of new
functional groups and availability of H-bond donors/acceptors on NMDAr interaction.
In an effort to elucidate the binding interactions of diaminodiphenyl compounds with
NMDAr the crystal structure of the NR2A subunit of NMDA was examined and the
agonist, glutamate, binding site was identified and the binding cavity was characterized.
(Fig 3, 5) The binding cavity is rich with hydrogen bond donors and acceptors and also
possesses the ability to interact heavily by Pi bonding interactions. Unsusbstituted
diaminodiphenyl compounds: 4,4’-diaminodiphenyl methane, 4,4’-diaminodiphenyl
sulfide and 4,4’-oxydianiline, were docked into the defined grid box and a consistant
binding motif was identified. The binding energies of the compounds were: -7.45
cal/mole, -7.63 kcal/mole, and -7.00 kcal/mole respectively. The compounds bound
consistently in near identical conformations resulting in strong Pi-cation interactions, as
well as, hydrogen bond interactions with THR 174. (Fig 6) The element which linked the
diaminodiphenyl compound did not signifigantly affect the binding the binding energy.
In order to address the effect of linker length on diaminodiphenyl interaction with
NMDAr 4,4’-ethylenedianiline was examined.(Fig 7) The favorable binding energy of 8.08 kcal/mole can be attributed to the hydrogen bonding at THR 174, as well as, THR
116 and ASP215. The binding orientation of 4,4’-ethylenedianiline was consistant with
the binding motif of other diaminodiphenyl compounds. Without the flexibility and the
bond angles offered by the ethylene linker these additional hydrogen bond interactions
would not be possible. The orientation of the ligand in the binding pocket along with the
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hydrogen bond to THR174 and favorable binding energy indicates that the longer more
flexible linker may be a more active antiepileptic compound than those diaminodiphenyls
with a shorter linker.
With linker element and length addressed the last linker variable to be examined was
linker substitution. Diaminobenzophenone, dapsone and 4,4'(hexafluoroisopropylidene)dianiline were modelled to address whether linker substitution
would alter the diaminodiphenyl affinity for NMDAr. Both diaminobenzophenone and
dapsone bind with favorable binding energy, -7.80 kcal/mole and -8.32 kcal/mole
respectively, and orientation. (Fig 8) Both compounds hydrogen bond to THR 174.
However, with bulky linker substitution, as in the case of 4,4'(hexafluoroisopropylidene)dianiline the binding energy is far less favorable, -4.05
kcal/mole, and the ligand does not interact at the predicted binding site. (Fig 9) When
considering the shape and size of the binding pocket, it is likely that 4,4'(hexafluoroisopropylidene)dianiline is too bulky to reach the binding site, as the cavity
narrows at several locations. Linker substitution does not appear to affect ligand binding
until the size of the ligand becomes prohibitive, preventing the ligand from reaching the
binding site on the NR2 subunit of NMDAr.
N-substitution resulting in secondary and tertiary amines does not appear to
significantly affect the binding energy of the diaminophenyl compounds.(Fig 10) The
N,N’-diacetyl derivative of 4,4’-diaminodiphenyl sulfide displayed a more favorable
binding energy, -9.32 kcal/mole, than the primary diaminodiphenyl compunds. This
binding energy is easily explained by the introduction of two hydrogen bond acceptors on
the acetyl groups, the ability of the secondary amine to donate hydrogen bonds and a
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deviation from the previously noted binding orientation that was consistant with the
primary diaminodiphenyls. 4,4'-methylene Bis(N,N-dimethylaniline) and the The N,N’pentacyclo derivative of 4,4’-diaminodiphenyl sulfide, are tertiary amines and lack the
ability to donate or receive hydrogen bonds. The binding orientation of 4,4'-methylene
Bis(N,N-dimethylaniline) is consistant with that of the primary diaminodiphenyl
compounds and the binding energy is -7.35 kcal/mole. The N,N’-pentacyclo derivative of
4,4’-diaminodiphenyl sulfide has a favorable binding energy, -8.13 kcal/mole, but does
not bind in an orientation consistant with other diaminodiphenyl compounds. The pi
stacking of the aromatic functional groups of both compounds is enough to present the
compound as a favorable binding lingand. However, if hydrogen bonding is essential for
diaminodiphenyls to elicit their antiepileptic properties, it could be assumed that 4,4'methylene Bis(N,N-dimethylaniline) and the N,N’-pentacyclo derivative of 4,4’diaminodiphenyl sulfide would not be active in a biologically relevant model. Further
examination of tertiary diaminodiphenyl compounds any conclusions could be drawn
regarding compound value as a ligand for NMDAr.
Several compounds examined address the effects of aromaticity and aromatic
substitution on ligand binding to NMDAr. 4,4'-methylene Bis(cyclohexyl amine) lacks
the aromatic rigidity and Pi interaction potential present in all of the other ligands
examined. The flexibility allows for more potential binding configurations, which is
contrasted by the inability to form many of the pi interactions displayed diaminodiphenyl
interactions with NMDAr. While the binding energy, -7.49 kcal/mole, and apperant
binding orientation of 4,4'-methylene Bis(cyclohexyl amine) appear to be similar to that
of the diaminodiphenyl compounds, the interactions responsible differ.(Fig 11) Pi-alkyl
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interactions and hydrogen bonding are the major forces behind 4,4'-methylene
Bis(cyclohexyl amine) binding. However, there is not conformation in which a hydrogen
bond interaction takes place with THR 174 as noted in diaminodiphenyl interactions with
NMDAr. Both halide and alkyl aromatic substitutions on diaminodiphenyl compounds
were examined. Both alkyl, 4,4'-methylene Bis(2,6-dimethylaniline), and halide, 4,4'methylene Bis(chloroaniline), substitution resulted in favorable binding energies, -8.28
kcal/mole and -8.58 kcal/mole respectively. Both compounds showed hydrogen bonding
interactions with THR 174. The only deviation from the binding motif displayed in
primary unsubstituted diaminodiphenyls is the orientation of the ligand within the
binding pocket.(Fig 12) Both substituted compounds presented two favorable binding
conformations within the binding pocket. Both conformations resulted in favorable
binding energy and hydrogen bonding interactions with THR 174. The data collected
suggests that aromatic substitution of diaminodiphenyls would have little effect on their
ability to interact with NMDAr and elicit an antiepileptic effect similar to that of primary
unsubstituted diaminodiphenyls.
Thiodi-indole and ethylenedi-indole were rationally designed in order to prevent Nhydroy metabolite formation while maintaining hydrogen bond donors at the amines. The
fully aromatic structure of the indole provides increased pi stacking which would
improve ligand binding affinity. When evaluated the binding energy of both thiodiindole,
-10.42 kcal/mole and ethylenediindole, -10.88 kcal/mole, are more favorable than the
diaminodiphenyl compounds evaluated. Both indole derivatives bound in the same
orientation as the parent diaminodiphenyl compounds and presented hydrogen bond
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interactions with THR 174.(Fig 13,14) Indole derivatization of diaminodiphenyl
compounds may be valuable leads and potent antiepileptic compounds.
The computational inhibition constants for those diaminodiphenyls which bound in a
favorable orientation and hydrogen bonded to THR 174 were all similar and ranged 7.38
µM to 517.15nM. (Table 2) Few structure activity relationship conclusions can be drawn
based solely on the computational inhibition constants. However, the improvement of
computational inhibition constant when diaminodiphenyl compounds are derivatized to
indole compounds was signifigant. Both compounds saw an improvement of ~100x in
computational inhibition constant. 4,4'-diaminodiphenyl sulfide has an inhibition constant
of 2.54 µM. When derivatized to thiodiindole, the inhibition constant is computed to
23.01 nM. 4,4’-ethylenedianiline has an inhibition constant of 1.19 µM, when derivatized
to ethylenediindole the inhibition constant is calculated to be 10.54 nM.
The in silico model of diaminodiphenyl compounds interactions with NMDAr
provides evidence that the antiepileptic effect of diaminodiphenyls may be elicited
through an interaction with the NR2A subunit of NMDA in a cavity which also contains
the agonist, glutamate, binding site. The activity of diaminodiphenyl compounds may be
mediated through a hydrogen bonding interaction with THR 174 within the binding
pocket. The conclusions drawn in this study is a foundation upon in vitro or in vivo
studies could be built.
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TABLE 1. Ligand binding energy and root mean squared deviation of the ligand root
from a reference point in space within the crystalline structure of NMDAr
NR2a subunit. Calculated in AutoDock

	
  

Binding	
  Energy	
  
(Kcal/mole)	
  
-‐8.58	
  
-‐8.32	
  
-‐8.28	
  
-‐8.08	
  
-‐7.80	
  
-‐7.63	
  
-‐7.49	
  
-‐7.45	
  
-‐7.35	
  
-‐7.00	
  
-‐4.05	
  
-‐10.88	
  
-‐10.42	
  
-‐9.32	
  

Ligand	
  
4,4'-‐methylene	
  Bis(chloroaniline)	
  
Dapsone	
  
4,4'-‐methylene	
  Bis(2,6-‐dimethylaniline)	
  
4,4'-‐ethylenedianiline	
  
Diaminobenzophenone	
  
4,4'-‐diaminodiphenyl	
  sulfide	
  
4,4'-‐methylene	
  Bis(cyclohexyl	
  amine)	
  
Diaminodiphenyl	
  methane	
  
4,4'-‐methylene	
  Bis(N,N-‐dimethylaniline)	
  
4,4'-‐Oxydianiline	
  
4,4'-‐(hexafluoroisopropylidene)dianiline	
  
Ethylenediindole	
  
Thiodiindole	
  
N,N'-‐diacetylthiodianiline	
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RMS	
  
41.34	
  
41.87	
  
42.29	
  
43.23	
  
41.96	
  
43.42	
  
44.22	
  
41.90	
  
39.50	
  
42.41	
  
38.45	
  
44.58	
  
43.87	
  
43.47	
  

TABLE 2. Computational inhibition constant based on ligand interaction with
NMDAr NR2a subunit. Calculated in AutoDock.
Ligand	
  
4,4'-‐methylene	
  Bis(chloroaniline)	
  
Dapsone	
  
4,4'-‐methylene	
  Bis(2,6-‐dimethylaniline)	
  
4,4'-‐ethylenedianiline	
  
Diaminobenzophenone	
  
4,4'-‐diaminodiphenyl	
  sulfide	
  
4,4'-‐methylene	
  Bis(cyclohexyl	
  amine)	
  
Diaminodiphenyl	
  methane	
  
4,4'-‐methylene	
  Bis(N,N-‐dimethylaniline)	
  
4,4'-‐Oxydianiline	
  
4,4'-‐(hexafluoroisopropylidene)dianiline	
  
Ethylenediindole	
  
Thiodiindole	
  
N,N'-‐diacetylthiodianiline	
  

Inhibition	
  
Constant	
  
517.15nM	
  
793.94nM	
  
845.46nM	
  
1.19uM	
  
1.92uM	
  
2.54uM	
  
3.25uM	
  
3.43uM	
  
4.12uM	
  
7.38uM	
  
1.07mM	
  
10.54nM	
  
23.01nM	
  
146.95nM	
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FIGURE 1. Proposed metabolic pathway of 4,4’-diaminodiphenyl sulfide, derived
based on the metabolism of aniline. N-hydroxy formation results in
toxicity which includes methemoglobinemia and carcinogenisis.
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Figure 2. Diaminodiphenyl compounds
A. 4,4’-diaminodiphenyl methane B. 4,4’-oxydianiline
C. 4,4’-diaminodiphenyl sulfide D. 4,4’-methylene Bis(2,6dimethylaniline) E. 4,4’-methylene Bis(chloroaniline) F. 4,4’-methylene
Bis(N,N-dimethylaniline) G. diaminobenzophenone
H. 4,4’-ethylenedianiline I. 4,4’-methylene Bis(cyclohexylamine)
J. 4,4’-(hexafluoroisopropylidene) dianiline K. N,N’-diacetyl
thiodianiline L. thiodiindole M. ethylenediindole N. dapsone
O. N,N’-pentacyclo thiodianiline
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N

Figure 3. Hydrogen bonding characteristics of the NMDAr NR2a subunit binding
cavity into which diaminodiphenyl compounds have been bound.
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Figure 4. Overlay of diaminodiphenyl compounds and derivatives within the
proposed binding pocket of NMDAr NR2a.

[Dapsone,
diaminobenzophenone,
diaminodiphenyl
methane,
oxydianiline,
diaminodiphenyl sulfide, ethylenedianiline, ethylenediindole, thiodiindole, methylene
Bis(chloroaniline), methylene Bis(2,6-dimethylaniline)]
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Figure 5. Aromatic binding characteristics of the NMDAr NR2a subunit binding
cavity into which diaminodiphenyl compounds have been bound.
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Figure 6. Binding interactions between diaminodiphenyl compounds with single element
linkers and NMDAr NR2a subunit. Hydrogen bonds in green and red, Pi
interactions in pink, Pi-sulfer interactions in yellow. All distances displayed
in angstroms.
4,4’-Oxyaniline

4,4’-Diaminodiphenyl methane

4,4’-Diaminodiphenyl sulfide
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Figure 7. Interactions between 4,4’-ethylenedianiline and NMDAr NR2a subunit,
examining the effects of linker length on diaminodiphenyl binding with
NMDAr NR2a sununit. Hydrogen bonds in green and red, Pi interactions in
pink. All distances displayed in angstroms.

4,4’-ethylenedianiline
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Figure 8. Interactions between diaminodiphenyl compounds with substituted linkers
and NMDAr NR2a subunit, examining the effects of linker substitution on
diaminodiphenyl binding with NMDAr NR2a sununit. Hydrogen bonds in
green and red, Pi interactions in pink, Pi-sulfer interactions in yellow. All
distances displayed in angstroms.

Dapsone

Diaminobenzophenone
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Figure 9. 4,4'-(hexafluoroisopropylidene)dianiline does not bind in the same binding
cavity as the other diaminodiphenyl compounds examined. Both binding
configurations differ in location significantly when compared to 4,4’diaminodiphenyl methane, in yellow. It is likely that the bulk of the
hexafluoroisopropylidene moiety is the limiting factor affecting the
compounds ability to enter the binding cavity.
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Figure 10. N-substituted diaminodiphenyl compounds lose the ability to hydrogen
bond. The binding orientation of these compounds overlap with the
binding orientations of unsubstituted diaminodiphenyls, but the interaction
with THR 174 is lost. Expected binding orientation represented by 4,4’diaminodiphenyl methane, in yellow.

N,N’-pentacyclo derivative
of 4,4’-diaminodiphenyl sulfide

Methylene Bis(N,N-dimethylaniline)

N,N’-diacetyl derivative
of 4,4’-diaminodiphenyl sulfide
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Figure 11. A. Binding orientation of 4,4'-methylene Bis(cyclohexyl amine) as compared
to 4,4’-diaminodiphenyl methane, in yellow.
B. Binding interactions between 4,4'-methylene Bis(cyclohexyl amine) and
NMDAr NR2a subunit.

A.

B.

B.
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Figure 12. Armomatic substituted diaminodiphenyl compounds both displayed 2
binding conformations, both of which hydrogen bonded with THR 174.
One major conformation for each compound overlapped the
conformation
of
unsubstituted
diaminodiphenyl
compounds.
Diaminodiphenyl methane in yellow.

Methylene
Bis(chloroaniline)

Methylene Bis(2,6dimethylaniline)
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Figure 13. A. Ethylenediindole binding orientation compared to 4,4’ethylenedianiline, in yellow. B. Thiodiindole binding orientation
compared to 4,4’-diaminodiphenyl sulfide, in yellow.

A
.

B
.
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Figure 14.Binding interaction of indole derivatives of diaminodiphenyl compounds
with NMDAr NR2a subunit

Ethylenediindole

Thiodiindole
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Epilepsy is a disorder characterized by the occurrence of seizures, which are periods
of abnormally excessive synchronous neuronal activity in the brain. Epileptic disorders
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have numerous etiologies, may occur at any age, typically require lifelong treatment, and
may significantly limit patient activity and quality of life. These disorders can be severely
debilitating, as seizures can manifest as major alterations in mental and physical states
and may even be life-threatening. Epilepsy is estimated to affect almost 70 million people
worldwide1,2 and has a staggering economic cost. For example, the annual economic cost
to the United State in 1995 for 2.3 million cases then prevalent was estimated to be $12.5
billion and the life-time cost for estimated 181,000 cases with onset in that year was
estimated to be $11.1 billion.3 In addition, there are tragic non-economic costs to patients
and their families.
Since 1989 about 15 new anti-epileptic drugs (AEDs) have become available in the
clinic providing patients and physicians with a number of treatment options 4,5 but some
literature reviews of clinical studies have concluded that even with the availability of
these new AEDs the proportion of patients who are seizure free after drug therapy has
climbed to only about 30%.5 In addition, adverse effects of AEDs can be serious enough
to negatively affecting a patient’s quality of life leading to issues surrounding patient
compliance with the medication dosing regimen.6 These side-effects include dizziness,
drowsiness, mental slowing, weight gain, metabolic acidosis, nephrolithiasis, glaucoma,
skin rash as well as movement and behavioral disorders among many others.6,7 The
problems posed by the side-effects are compounded by the requirement for multiple-drug
therapy for adequate seizure control in many patients.8
Thus there is still a pressing need for the development additional AEDs with novel
mechanism of action that can provide patients and physicians with alternative treatment
options. Furthermore, it is clear that numerous and diverse underlying pathophysiological
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mechanisms contribute to the epileptic syndrome. Therefore, access to a spectrum of
AEDs, with different modes of action, will allow for optimizing therapy to suit the
pharmacological and toxicological profiles of individual patients so as to improve
tolerability and long-term treatment success. The global AED market is a multibilliondollar enterprise that is still growing and the market for pharmaceutical treatment of
epilepsy generated $12 billion in 2008.9 Given this background, the development of an
AED with a novel mechanism of action is likely to be economically successful if it can
show superior efficacy even in a subset of patients.
Diaminodiphenyl compounds have been characterized as potent anticonvulsants with
little notable acute toxicity.10 Though the activity of diaminodiphenyl compounds has
been described, little is known about the mechanism of action of these compounds. In
order to better understand the mechanism by which diaminodiphenyl compounds exert
their anticonvulsive properties, a series of diaminodiphenyl compounds were examined in
animal models of epilepsy in an attempt to elucidate a structure activity relationship.
Diaminodiphenyl compounds were evaluated in both the maximal electroshock
(MES) and 6Hz psychomotor seizure models in order to elucidate the anticonvulsive
properties. The MES model determines a compounds ability to prevent seizure spread
when neuronal circuits are active. Similar to the MES model, the 6Hz model examines a
compounds ability to prevent electrically induced seizures, the major difference being the
intensity of the electrical stimulation.

Animals
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Species used in the animal studies were CF#1 mice and Sprague-Dawley rats.
Animals were given free access to food and water when not under active evaluation. All
animal care policies were adhered to as prescribed by the National Research Council and
all studies were completed in the labs of the NINDS Anticonvulsant Screening Program.

MES
Seizures are induced, in mice or rats (n=4), using 50 mA or 150 mA alternating
current respectively for 2 seconds using corneal electrodes primed with an electrolyte
solution containing 0.5% tetracaine HCL anesthetic. Diaminodiphenyl compounds were
delivered by IP injection at doses of 30, 100 and/or 300 mg/Kg at a volume of 0.01mL/g.
Neuroprotection was characterized as the abolition of the tonic phase of seizure
development. 11,12,13

6Hz
Seizures are induced in mice (n=4), using 32 mA alternating current for 3 seconds
using corneal electrodes primed with an electrolyte solution containing 0.5% tetracaine
HCL anesthetic. Diaminodiphenyl compounds were delivered by IP injection at doses of
30, 100 and 300 mg/Kg at a volume of 0.01mL/g. Neuroprotection was characterized as
the abolition of a brief clonic phase followed by automatistic behaviors.14

Acute toxicity
The acute neurotoxicity of the compounds was evaluated in mice (n=8) using the
rotorod test, and using the positional sense and gait and stance tests. Acute neurotoxicity
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was characterized as 3 failures of an animal to remain on a rotating, 3.2 cm knurled rod
for 1 min at 6 rpm. Diaminodiphenyl compounds were delivered by IP injection at doses
of 30, 100 and 300 mg/Kg prior to evaluation in the toxicity screens. Animals were
evaluated at both 0.5 and 2 h post administration. Positional sense and gait and stance
tests were used to evaluate gait, behaviors, muscle dysfunction and other indications of
neurotoxicity.

Compounds which displayed significant neuroprotection were further evaluated in the
MES and 6Hz models using relevant doses (30, 100 or 300 mg/Kg) at time points of 0.25,
0.5, 1, 2, and 4 hours. Compounds were delivered through IP injection, as previously
described, or orally.
The compounds evaluated were chosen to explore several structural variable in order
to determine the effect functional different functional groups and structural differences
will have on diaminodiphenyl anticonvulsive activity. Structural differences evaluated
were: linker element and length, linker substitution, aromatic substitution, aromaticity,
and amine substitution. A majority of the diaminodiphenyl compounds possess
anticonvulsive properties, though the dose and duration of anticonvulsive effects vary
based on the structure of the compounds (Table 1, 2).
4,4’-diaminodiphenyl methane 4,4’-diaminodiphenyl sulfide, and oxydianiline were
evaluated to elucidate whether the element that links the aniline moiety effects the
anticonvulsive potential of a diaminodiphenyl compound. In both MES and 6Hz animal
models oxydianiline was a leading anticonvulsant, when compared to 4,4’diaminodiphenyl methane 4,4’-diaminodiphenyl sulfide. While 4,4’-diaminodiphenyl
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sulfide was as effective in the MES model acting as an anticonvulsant at a dose of 100
mg/Kg at both the 30 minute and 2 hour time points. However, oxydianiline was a longer
acting anticonvulsant when evaluated in the 6Hz model acting at a dose of 100 mg/Kg for
2 hours, while 4,4’-diaminodiphenyl sulfide and 4,4’-diaminodiphenyl methane were
only effective at the same dose for 30 minutes. At an increased dose of 300 mg/Kg, both
4,4’-diaminodiphenyl methane and 4,4’-diaminodiphenyl sulfide were both effective
anticonvulsants in the 6 Hz model for up to 2 hours. When evaluated in the MES model,
4,4’-diaminodiphenyl methane was only effective at a dose of 300 mg/Kg with a duration
of 2 hours. The superior anticonvulsive properties of oxydianiline may be a result of the
higher electronegativity of the oxygen linker between the aniline moieties. The
differences in activity between the carbon and sulfur linkers cannot be explained by
electronegativity, but sulfur’s lone pairs of electrons may be a favorable characteristic
responsible for the increased anticonvulsive effects noted in the MES model, though this
conclusion is contrasted by the results seen in diaminodiphenyl compounds which have
longer linker groups.
4,4’-ethylenedianiline and 4-aminophenyldisulfide were evaluated to determine
whether the length of the linker would affect the anticonvulsive properties of
diaminodiphenyl compounds. The results contrasted the conclusions drawn based on the
single element linkers. The 4,4’-ethylenedianiiline was a more potent anticonvulsant than
diaminophenyldisulfide, as well as, all of the single element linker diaminodiphenyl
compounds that were evaluated. 4,4’-ethylenedianiline provided short acting
neuroprotection at at a dose of 30 mg/Kg, which persisted through the 2 hour time point
when the dose was increased to 100 mg/Kg in the MES model. 4-aminophenyldisulfide
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was a much slower acting anticonvulsant in the MES model showing no effects at the 30
minute time point at 100 mg/Kg, though at the 2 hour time point it was an effective
anticonvulsant. At a dose of 300 mg/Kg anticonvulsive properties were noted at the 30
minute time point, though toxicity prevented observations at the 2 hour time point at the
same dose in the MES model. Results were similar in the 6Hz model, with the notable
difference being the onset and duration of action of 4-aminophenyldisulfide which was
noted at the 30 minute time point but lost at the 2 hour time point at a dose of 100 mg/Kg.
The increased anticonvulsive properties of the 4,4’-ethylenedianiline and the less
favorable anticonvulsive effects elicited by 4-aminophenyldisulfide suggest that a longer
linker which allows for ligand flexibility is a favorable characteristic lending to increased
anticonvulsive effects. The anticonvulsive effects of 4,4’-ethylenedianiline were superior
to the effects elicited by oxydianiline which suggests that linker length and flexibility is
likely more important than lone pairs of electrons on the linker.
Substituted linkers of variable length were were also evaluated in order to determine
whether linker substitution affects diaminodiphenyl anticonvulsive properties. Dapsone,
diaminobenzophenone, diaminobenzanilide, and 4,4’-(hexafluoroisopropylidene)dianiline
provide various linker substitutions of varying size and linker lenth and providing insight
into diaminodiphenyl anticonvulsant potential. Both dapsone and diaminobenzophenone
present oxygen substituted single element linkers introducing hydrogen bond acceptors in
the linker region. Both compounds are neuroprotective at a dose of 30 mg/Kg, though
dapsone is the only compound whose effects persisted to the 2 hour time point, while
diaminobenzophenone required a dose of 100 mg/Kg to persist to the 2 hour time point in
the MES model. When evaluated in the 6Hz model both compounds showed no activity
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at the low dose, though both were effective anticonvulsants at a dose of 100 mg/Kg for
both time points. Diaminobenzanilide presents a longer linker with an amido group linker
which introduces a hydrogen bond acceptor, as well as, nitrogen into the linker. At a dose
of 100 mg/Kg anticonvulsive properties were only noted at the 30 minute time point,
while a dose of 300 mg/Kg allowed the anticonvulsive properties to persist to the 2 hour
time point in both models. When compared to other compounds evaluated an amido
linker is not favorable and requires a high dose in order to provide neuroprotection in
both tests. 4,4’-(hexafluroisoproylidene) dianiline has a bulky linker to determine
whether compound size affects diaminodiphenyl anticonvulsive properties. In all tests
4,4’-(hexafluroisoproylidene) dianiline failed to elicit neuroprotective effects, suggesting
that ligand size is an important factor in the anticonvulsive activity of diaminodiphenyl
compounds.
The effect of aromatic substitution was addressed by testing 4,4’-methylene Bis(2,6dimethylaniline) and methylene Bis(chloroaniline). At a dose of 100 mg/Kg and 300
mg/Kg respectively, 4,4’-methylene Bis(2,6-dimethylaniline) and methylene
Bis(chloroaniline), displayed anticonvulsant effects lasting for two hours in the MES
model. 4,4’-methylene Bis(2,6-dimethylaniline) performed slightly better than methylene
Bis(chloroaniline) providing neuroprotection for 30 minutes at a dose of 100 mg/Kg,
though both provided the same neuroprotection at both time points at a dose of 300
mg/Kg. Neither compound showed significant improvement in anticonvulsive effects and
therefore aromatic substitution is of little consequence or benefit.
In order to address whether aromaticity plays a role in the noted anticonvulsive
properties of diaminodiphenyl compounds, 4,4’-methylene Bis(cyclohexylamine) was
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tested. No activity was noted and testing was discontinued at a dose of 100 mg/Kg due to
toxicity in test animals. Further testing of non-aromatic compounds would be needed to
draw any conclusion regarding the effect of aromaticity on the anticonvulsive properties
of diaminodiphenyl compounds.
Lastly, amine substitution was addressed by testing 4,4’-methylene Bis(N,Ndimethylaniline). By substituting the amine of diaminodiphenyl compounds, hydrogen
bond donors are eliminated. In both the MES and 6Hz model 4,4’-methylene Bis(N,Ndimethylaniline) failed to provide neuroprotection at any dose. This provides evidence
that hydrogen bond interactions at the amine group may be necessary for
diaminodiphenyl compounds to elicit their anticonvulsive properties, though further
testing would be necessary to confirm this conclusion.
With a majority of the compounds tested presenting anticonvulsive properties at
similar doses, it is also beneficial to explore the link between diaminodiphenyl structure
and toxicity. (Table 3) The most commonly noted toxicity is the animals’ failure to grasp
the rotorod and loss of the righting reflexes. In all cases these toxicities are only noted in
the highest tested dose, 300 mg/Kg. These test failures could be attributed to a sedative
effect which may present as a result of the high dose of an ion channel antagonist, though
further testing would be needed to support that conclusion. In the case of 4,4’-methylene
Bis(2,6-dimethylaniline) and diaminodiphenyl methane, the rotorod test and righting
reflex failures were only noted at the 30 minute time point, while the compounds’
antiepileptic effects are noted to persist to the later time point of 2 Hr. This suggests
temporary reversible effects which are responsible for the noted test failures and further
supports a sedative effect.
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Dapsone, a drug used to treat leprosy, when given at high doses, resulted in a failure
in the rotorod test as well as behavioral changes in the animals. At a dose of 300 mg/Kg
animals began to stretch and roll. It is unclear from these studies whether the stretching
and rolling behaviors are manifestations of neurotoxicity or psychoactivity of the
compound in the test animals. As dapsone is a drug which has been on the market for
some time, it is fairly safe to conclude that the drug is not neurotoxic at clinical doses.
Another noted effect elicited by a 300 mg/Kg dose of diaminobenzanilide and
diaminobenzophenone was muscle spasm or tremor. The common functional group noted
between these two compounds is the carbonyl group in the linker region of the
compound. The carbonyl functional group presents a hydrogen bond acceptor and could
result in a tighter receptor binding. The additional hydrogen bond acceptor may also
result in binding to receptors untargeted by diaminodiphenyls which lack carbonyl
groups. Off target binding activity could also present as tremors/muscle spasms.
Only two compounds tested caused death in experimental animals. 4aminophenyldisulfide toxicity presented as sedation at the 30 minute time point at 300
mg/Kg dose, by the 2 hour time point all of the test subjects had expired. The disulfide
linker is likely responsible for the adverse effects. Disulide could easily disrupt protein
structure, which can result in loss of receptor functions leading to death. The other
compound that caused death in test subjects was 4,4’-methylene Bis(cyclohexylamine).
4,4’-methylene Bis(cyclohexylamine) was toxic at a lower dose than other test
compounds and resulted in subject death at a dose of 100 mg/Kg by the 30 minute
timepoint. 4,4’-methylene Bis(cyclohexylamine) did not display any antiepileptic
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activity. The rapid onset of toxicity does not implicate the receptor based toxicity noted
in other test compounds.
Diaminodiphenyl compounds may be a valuable lead for the development of a novel
antiepileptic compound. Thought there are key features which are necessary and some
which need to be avoided when developing lead compounds. Linker element does not
appear to drastically effect anticonvulsive properties. Linker length, flexibility and
potential metabolite formation would be valuable characteristics to consider. Based the
toxicity of diaminobenzophenone and diaminobenzanilide, carbonyl containing linkers
will likely present adverse effects. The most important characteristic to consider when
designing a diaminodiphenyl antiepileptic compound is the availability of hydrogen bond
donation at the amine moiety.
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Table 1. Maximal Electroshock model of epilepsy in mice. Results displayed show the
lowest dose at which neuroprotection was observed, as well as, the dose
required to exhibit neuroprotection for the duration of the experiment. All doses
were delivered by IP injection.

Compound	
  
Dapsone	
  
Diaminobenzophenone	
  
4,4'-‐ethylenedianiline	
  
4,4'-‐Methylene	
  Bis(2,6-‐dimethylaniline)	
  
Diaminodiphenyl	
  sulfide	
  
Oxydianiline	
  
4-‐aminophenyldisulfide	
  
Diaminobenzanilide	
  
Diaminodiphenyl	
  methane	
  
Methylene	
  Bis(chloroaniline)	
  
4,4'-‐(hexafluoroisopropylidene)	
  dianiline	
  
4,4'-‐Methylene	
  Bis(cyclohexylamine)	
  
4,4'-‐methylene	
  Bis(N,N-‐dimethylaniline)	
  

Dose	
  
(mg/Kg)	
  
30	
  
30	
  
30	
  
100	
  
100	
  
100	
  
100	
  
100	
  
300	
  
300	
  
Neg	
  
Neg	
  
Neg	
  

Time	
  
of	
  
effect	
  
2	
  Hr	
  
0.5	
  Hr	
  
0.5Hr	
  
2	
  Hr	
  
2	
  Hr	
  
2	
  Hr	
  
2	
  Hr*	
  
0.5	
  Hr	
  
2	
  Hr	
  
2	
  Hr	
  
-‐	
  
-‐	
  
-‐	
  

Dose	
  
(mg/Kg)	
  

Time	
  
of	
  
Effect	
  

	
  
100	
  
100	
  
-‐	
  
-‐	
  
-‐	
  
300	
  
300	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  

	
   r	
  
2	
  H
2	
  Hr	
  
-‐	
  
-‐	
  
-‐	
  
0.5	
  Hr	
  
2	
  Hr	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  

*Neuroprotection was not noted in the 30 minute time point for a dose of 100 mg/Kg
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Table 2. 6Hz model of epilepsy in mice. Results displayed show the lowest dose at which
neuroprotection was observed, as well as, the dose required to exhibit
neuroprotection for the duration of the experiment. All doses were delivered by
IP injection.

Dose	
  
(mg/Kg)	
  

Compound	
  
4,4'-‐ethylenedianiline	
  
Dapsone	
  
Diaminobenzophenone	
  
Oxydianiline	
  
4,4'-‐Methylene	
  Bis(2,6-‐dimethylaniline)	
  
Diaminobenzanilide	
  
Diaminodiphenyl	
  methane	
  
Diaminodiphenyl	
  sulfide	
  
4-‐aminophenyldisulfide	
  
Methylene	
  Bis(chloroaniline)	
  
4,4'-‐Methylene	
  Bis(cyclohexylamine)	
  
4,4'-‐(hexafluoroisopropylidene)	
  dianiline	
  
4,4'-‐methylene	
  Bis(N,N-‐dimethylaniline)	
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100	
  
100	
  
100	
  
100	
  
100	
  
100	
  
100	
  
100	
  
100	
  
300	
  
Neg	
  
Neg	
  
Neg	
  

Time	
  
Time	
  
Dose	
  
of	
  
of	
  
(mg/Kg)	
  
Action	
  
Action	
  
2	
  Hr	
  
-‐	
  
-‐	
  
2	
  Hr	
  
-‐	
  
-‐	
  
2	
  Hr	
  
-‐	
  
-‐	
  
2	
  Hr	
  
-‐	
  
-‐	
  
0.5	
  Hr	
  
300	
  
2	
  Hr	
  
0.5	
  Hr	
  
300	
  
2	
  Hr	
  
0.5	
  Hr	
  
300	
  
2	
  Hr	
  
0.5	
  Hr	
  
300	
  
2	
  Hr	
  
0.5	
  Hr	
  
300	
  
0.5	
  Hr	
  
2Hrs	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
  

Table 3. Results of acute neurotoxicity screening. Test failures and adverse events are
noted at the dose where observations were made. All doses were delivered by IP
injection.
Dose	
  
(mg/Kg)	
  
100	
  

Compound	
  
4,4'-‐Methylene	
  Bis(cyclohexylamine)	
  
Methylene	
  Bis(chloroaniline)	
  

300	
  

Oxydianiline	
  

300	
  

Diaminobenzanilide	
  

300	
  

4-‐aminophenyldisulfide	
  

300	
  

Diaminobenzophenone	
  

300	
  

Diaminodiphenyl	
  methane	
  

300	
  

Diaminodiphenyl	
  sulfide	
  

300	
  

4,4'-‐Methylene	
  Bis(2,6-‐dimethylaniline)	
  

300	
  

Dapsone	
  

300	
  

4,4'-‐ethylenedianiline	
  

300	
  

4,4'-‐(hexafluoroisopropylidene)	
  dianiline	
  
4,4'-‐methylene	
  Bis(N,N-‐dimethylaniline)	
  

Neg	
  
Neg	
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Test(s)	
  
failed	
  
-‐	
  
Rotorod	
  
test	
  
Rotorod	
  
test	
  
Rotorod	
  
test	
  
Righting	
  
Reflex	
  
Rotorod	
  
test	
  
Righting	
  
Reflex,	
  
Rotorod	
  
test	
  
Righting	
  
Reflex,	
  
Rotorod	
  
test	
  
Rotorod	
  
test	
  
Rotorod	
  
test	
  
Rotorod	
  
test	
  
-‐	
  
-‐	
  

Noted	
  
toxicity	
  
Death	
  
-‐	
  
-‐	
  
Muscle	
  
Spasm	
  
Death	
  
Tremors	
  

-‐	
  

-‐	
  

-‐	
  
Stretching	
  
and	
  
Rolling	
  
-‐	
  
-‐	
  
-‐	
  

MANUSCRIPT 3

SYNTHESIS OF RATIONALLY DESIGNED DIAMINODIPHENYL DERIVATIVES
In preparation: Bioorganic and Medicinal Chemistry Letters

Kyle R. Scully, Kevin Colizza, Brenton DeBoef, David R. Worthen
Interdisciplinary Neurosciences, University of Rhode Island, Kingston, RI, USA
Department of Chemistry, University of Rhode Island, Kingston, RI, USA
Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA

Corresponding Author:

David R. Worthen, PhD.
Biomedical and Pharmaceutical Sciences
University of Rhode Island
7 Greenhouse Rd
Kingston, RI, 02881, USA
Phone: 401.874.5016
DWorthen@ds.uri.edu

54

Diaminodiphenyl compounds have been shown to exert potent anticonvulsive
properties in animal models of epilepsy. It has been purported that diaminodiphenyl
compounds exert their anticonvulsive effects through interactions with the N-methyl-Daspartate receptor.1 In silico evaluation of several diaminodiphenyl compounds has
provided further evidence that NMDAr, more specifically the NR2 subunit, is likely the
site of action for diaminodiphenyl compounds.
Though acute toxicity evaluation indicates that many diaminodiphenyl compounds
are not neurotoxic, aniline, a major functional group of diaminodiphenyl compounds, is
known to be toxic. The major toxicity resulting from aniline exposure is
methemoglobinemia, a blood toxicity which results in the inability to transport oxygen.2
Additionally, the EPA has classified aniline as a probable carcinogen. The metabolism of
aniline is responsible for both toxic mechanisms. Oxidation of the amino group forms the
key toxic intermediate, N-hydroxyaniline (Fig 1).
Diaminodiphenyl compounds, which possess aniline moieties, are likely to be toxic
during chronic exposure, even at low doses. Rational drug design techniques offer an
opportunity to eliminate the toxic potential while maintaining or improving the
anticonvulsive properties of diaminodiphenyl compounds. Through modification of the
amino groups of diaminodiphenyls it may be possible to prevent the metabolic formation
of the N-hydroxy intermediate which is proposed to result in methemoglobinemia and
DNA adduct formation. Successful design and synthesis of a diaminodiphenyl derivative
could lead to the development of an NMDAr antagonist which could be used to treat
many indications, including epilepsy, neuropathic pain and mood disorders.
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Materials and Methods
Chemicals
All chemical reagents and solvents were purchased from Sigma Aldrich or Fisher
Scientific.

N,N’-diacetyl-diaminodiphenyl sulfide derivative (Scheme 1)
4,4’-diaminodiphenyl sulfide (1.00 g, 4.62 mmol) was dissolved in THF and added
dropwise to an excess of acetyl chloride containing potassium carbonate (700.0 mg, 5.06
mmol). The reaction was stirred at room temperature for 30 minutes. Product was then
collected by vacuum filtration. The product was washed with cold THF before being
dried in a vacuum desiccator.

N,N’-azapentacyclodiphenyl sulfide (Scheme 2)
4,4’-diaminodiphenyl sulfide (1.00 g, 4.62 mmol) was dissolved in a minimum
volume of acetone (40 mL). At room temperature the 4,4’-diaminodiphenyl sulfide
solution was added dropwise into a reaction mixture of 1,4-dibromobutane (3.35g, 15.5
mmol) and potassium carbonate (700.0 mg, 5.06 mmol) in acetone/water. When all
reactants are added the final solvent is 95% acetone/water. The reaction was allowed to
stir at room temperature overnight before being evaporated prior to purification. The
resulting reaction mixture was taken up in 50/50 ethyl acetate and water. The aqueous
phase was washed three times with ethyl acetate and the organic fractions were pooled.
Using a rotary evaporator the organic phase was adsorbed to silica and packed into a
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column for purification by flash chromatography. N,N’-azapentacyclodiphenyl sulfide
was collected yielding 751 mg, 50.39%.
1

H-NMR (300 MHz, DMSO) ᵟ 7.26-6.99 (d, 4), 6.62-6.37 (d, 3.97), 3.27-3.10 (t,

8.06), 2.02-1.85 (t, 7.24). (Fig 2) 13C NMR (126 MHz, DMSO) δ 147.32, 133.02, 129.34,
121.23, 112.79, 112.53, 47.73, 40.57, 40.48, 40.40, 40.31, 40.23, 40.15, 25.43, 25.39,
25.37 (Fig 3).

Indole derivatives of diaminodiphenyl compounds
Method 1(Scheme 3)
The synthisis of diindole derivatives was derived from the methods of Cho, et al.
2000, and was completed in 10 ml of 1,4-dioxane, under argon. Diaminodiphenyl
compounds (diaminodiphenyl sulfide: 1.08 g, 5.0 mmol; 4,4-ethylenedianiline: 1.06 g, 5
mmol) were combined with triethanolamine (133 µL, 2 mmol). Ruthenium chloride (20.7
mg, 0.1 mMol), tin chloride (225 mg, 2.0 mmol) and triphenylphosphine (157.5 mg, 0.6
mmol) were added as catalysts. The reaction was stirred in a sealed reaction vial at 180
o

C for 20 hours.3 The resulting reaction mixture was adsorbed to silica packed into a

column for purification by flash chromatography.
Method 2 (Scheme 4)
The synthisis of diindole derivatives was derived from the methods of Cho, et al.
2007, and was completed in 10 ml of 1,4-dioxane, under argon. Diaminodiphenyl
compounds (diaminodiphenyl sulfide: 1.08 g, 5.0 mmol; 4,4-ethylenedianiline: 1.06 g, 5
mmol) were combined with dibromoethane (22 µL, 250 µmol) at a 20:1 mole ratio in
order to prevent piperazine polymer formation. Ruthenium chloride (20.7 mg, 0.1 mmol)
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and triphenylphosphine (786.9 mg, 3 mmol) were added as catalysts. The reaction was
stirred in a sealed reaction vial at 180 oC for 20 hours.4 The resulting reaction mixture
was adsorbed to silica packed into a column for purification by flash chromatography.

Flash chromatography
Using a Teledyne Isco CombiFlash® Rf 200 the reaction mixture was purified
through a RediSepRf High Performance Gold 12g HP Silica column (Teledyne Isco inc.)
using a hexane/ethyl acetate gradient with a 30 mL/min flowrate and a maximum
pressure of 400 psi (Fig 4). Fractions were collected by an automated fraction collector
monitoring 253 and 255 nm wavelengths.

Liquid chromatography
Using a Thermo Scientific liquid chromatograph reaction products were separated
using a ODS Hypersil C-18 column at a flow rate of 250 µL/min using a gradient of 0.1%
aqueous acetic acid and acetonitrile. (Appendix 1)

Results and Discussion
Based on the toxicity of aniline, it is likely that diaminodiphenyl compounds would
lead to adverse effects with chronic exposure. However, the potent anticonvulsive
properties of the compound class cannot be overlooked. Using a computer based model
of receptor-ligand interactions it is possible to design compounds that cannot be
metabolized in a similar fashion to aniline while maintaining the compounds ability to
interact at the NMDAr NR2 subunit binding site.
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By substituting the amino groups of the diaminodiphenyl compound class the
intention is to prevent the N-hydroxy metabolite formation. This has been addressed in
the synthesis of both the diacetyl- and N,N’-azapentacyclo- diaminodiphenyl sulfide
derivatives. These modifications to the amino group result in secondary and tertiary
amine formation, which will result in a drastically different hydrogen bonding potential
from that of the parent diaminodiphenyl compounds, with the diacetyl- derivative having
decreased hydrogen bonding potential due to the lack of a permanent dipole and the
azapentacyclo- derivative lacking hydrogen bonding groups altogether.
Upon further evaluation in computer based models and results gathered in animal
models of epilepsy, it was determined that hydrogen bonding appears to be an important
factor in a diaminodiphenyl compound’s anticonvulsive potential. For this reason the
consideration and synthesis of several proposed azacyclo derivatives, was discontinued
(Fig 5).
Chemical characterization of the diacetyl- derivative of diamindiphenyl sulfide
revealed product decomposition. Unlike previously characterized diaminodiphenyl
derivatives, product separation was not easily accomplished by flash chromatography
using a silica stationary phase. Using liquid chromatography and solid phase extraction
techniques the mono- and di- substituted derivatives of diaminodiphenyl sulfide were
separated across a C-18 column in acetonitrile/ 0.1% aqueous acetic acid mobile phase
(Appendix 1). The mass spectrometry data suggests that the compound may be breaking
down from the diacetylated derivative to the monoacetylated derivative of
diaminodiphenyl sulfide (Fig 6). The extracted ion trace of the diacetyl- derivative of
diaminodiphenyl sulfide, purified by solid phase extraction, support the conclusion that

59

the stability of N,N’-diacetyl-diaminodiphenyl sulfide needs to be evaluated further. The
LCMS data shows a very small, though detectable, peak with a higher retention time in
SPE purified product, which can be characterized as the monoacetyl- derivative (Fig 7).
Further method development and compound stability studies would be necessary to
create a stable diacetyl- derivative of diaminodiphenyl sulfide.
The synthesis of the di-indole derivative of 4,4’-ethylenedianiline and
diaminodiphenyl sulfide has been challenging. The methods for indole synthesis are
based on the synthesis of indoles from substituted anilines as described by Cho, et al.3
The ruthenium/tin catalyzed reaction between triethanolamine and diaminodiphenyl
compounds was run under the prescribed conditions (Scheme 3). The reaction did not
result in the formation of the intended product in the conventionally heated or microwave
synthesis experiments. Upon repeated failure of this method of indole synthesis,
alternative methods were pursued.
The ruthenium catalyzed reaction between dibromoethane and diaminodiphenyl
sulfide (Scheme 4) also produced zero yield of the diindole derivate. However, the
reaction did take place using this method. The first step of the reaction may have proceed
resulting in the formation of N-bromoethane substituted diaminodiphenyl sulfide
derivative. The mass spectroscopy data suggests that the intended indole product was not
formed (Fig 8). The mono-substituted product is likely a result of the molar ratio of the
reagents, which is low in order to prevent piperazine polymer formation. If additional
equivalents of 1,2-dibromoethane were added upon reaction completion and the reaction
were repeated, the reaction may result in the intended N,N’-bromoethane intermediate
formation. Reactant ratios could be optimized in order to improve the efficiency of the
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reaction, leading to a higher yield. If the reaction results in the N,N’-bromoethane
intermediate upon completion, it could be possible to modify the halide, replacing the
bromine with iodine. The iodine group is a far better leaving group and could help to
foster the intramolecular reaction forming the intended indole derivatives.
The rational design of diaminodiphenyl derivatives could provide a potent
anticonvulsant. The most promising derivative addressed in this work is the diindole
derivative. If the computer based model of receptor ligand interactions is accurate, the
resulting derivatives would be 100 times more potent than the parent compound and the
toxic metabolites encountered with the parent compound could not be formed. Indoles,
however, pose an additional challenge: delivery. Indoles are highly lipophilic and not
readily water soluble. Should the indole derivatives of diaminodiphenyl compounds
present potent anticonvulsive properties with limited toxicity, formulation and delivery of
the compound would need to be addressed.
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Scheme 1. Diacetyl derivative synthesis
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Scheme 4. Indole synthesis - dibromoethane
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Figure 1. Proposed metabolic pathway of 4,4’-diaminodiphenyl sulfide, derived
based on the metabolism of aniline. N-hydroxy formation results in toxicity which
includes methemoglobinemia and carcinogenesis.
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Figure 2. Proton NMR of N,N’-azapentacyclodiaminodiphenyl sulfide.
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Figure 3. Carbon NMR spectrum of N,N’-azapentacyclodiaminodiphenyl sulfide.
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Figure 4. Azacyclo derivatives which were not purified based on the modeling and in
vivo data collected with N,N’-azapentacyclodiaminodiphenyl sulfide.
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Figure 5. Mass spectrograph of N,N’-diacetyl-diaminodiphenyl sulfide.

71

Figure 6. Extracted ion traces of solid phase extraction purified N,N’-diacetyldiaminodiphenyl sulfide injected immediately after SPE.
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Figure 7. Mass spectrograph of diindole synthesis method 2 (Scheme 4) product
provides evidence that the synthesis of desired derivative was not
successful.
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CONCLUSION AND FUTURE STUDIES

The results of the present study have shown that a series of simple diaminodiphenyl
(DADP) compounds that are structurally distinct from known anti-epileptic compounds,
bind in a conserved orientation and with similar binding interactions within a solvent
accessible cavity of N-methyl-D-aspartate receptor NR2 subunit which contains the
agonist binding site. Transfected cell-based assays in which mammalian NMDAr is
expressed in Xenopus oocytes suggest that these compounds inhibit the activity of
NMDAr (Appendix 2). Furthermore, these DADP compounds exert profound in vivo
anticonvulsant activity by preventing the initiation and propagation of seizures in rats and
mice in several seizure models.
Data collected in silico suggests that variability in the linker does not drastically
affect the compounds’ binding energy; however, substitution can lead to a change in the
binding motif or keep the compound from entering the binding pocket altogether.
Notably, the in silico and in vivo provide evidence that N-hydrogen bonding is an
essential component to the binding interaction between NMDAr and DADPs, as well as,
to the anticonvulsive effects elicited in rat and mouse models of epilepsy. This data has
guided the design of novel diaminodiphenyl derivatives, resulting in the design diindole
derivatives and the exclusion of several earlier generations of diaminodiphenyl
derivatives based on structure activity relationship and compound stability. Though these
indole derivatives have not yet been synthesized, computational binding energies and
inhibition constants indicate that the anticonvulsive properties of these compounds could
exceed that of previously examined diaminodiphenyl compounds. Should the current
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methods to synthesisze diindole derivatives fail it may be necessary to pursue an
alternative method.
Future studies should aim to characterize the diaminodiphenyl binding pocket on
NMDAr, where diaminodiphenyl compounds actively bind and modulate NMDAr
activity. The binding site can be further characterized by further refining in silico models.
Examining the effects of flexible amino acid sidechains will further elucidate the
characteristics of the binding site on the NMDAr NR2 subunit. These characteristics can
be used to select key amino acids, including THR 174 elucidated in our studies, to design
point mutants of the NMDAr NR2 subunit. The effects of point mutations could be
examined using in silico modeling techniques to determine the effects of point mutations
on NMDAr structure and diaminodiphenyl binding. Furthermore, point mutations of
NMDAr can be examined in vitro using electrophysiology based techniques; contrasting
the function of wt NMDAr to mutant forms of NMDAR in Xenopus oocyte.
Electrophysiology based studies will provide evidence of diaminodiphenyl antagonism of
NMDAr in a relevant biological model, as well as, elucidating the mechanism by which
diaminodiphenyls exert their antagonism. Characterization of the NMDAr
diaminosiphenyl binding site has the potential to offer a potent druggable site of action
for disorders of glutamate, including epilepsy.
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APPENDIX 1
ISOLATION OF N,N’-DIACETYLDIAMINODIPHENYL SULFIDE BY LIQUID
CHROMATOGRAPHY AND SOLID PHASE EXTRACTION
The separation of the mono- and di- acetyl products of diaminodiphenyl sulfide was
not completed successfully by silica based flash chromatography, as was the case with
other diaminodiphenyl derivatives were. The use of a C-18 column was necessary and an
appropriate gradient method was elucidated in order to efficiently separate the products.
All liquid chromatographic separations were performed on a Thermo Scientific
Accela pump using a Thermo Scientific ODS Hypersil C-18 2.1x100 mm, 5um column.
Samples were injected inline by a Thermo Scientific HTS PAL Auto-sampler. Products
were separated using a gradient mobile phase of 0.1% aqueous acetic acid and
acetonitrile.
Mobile Phase Gradient
Time
(min)

Acetonitrile
(%)

0

0.1% aqueous
acetic acid
(%)
80

2

80

20

15

2

98

20

2

98

22

80

20

25

80

20

20

Initial studies using a neutral aqueous mobile phase resulted in poor compound
separation. Addition of 0.1% acetic acid separated mono- and di-acetyl derivatives of
diaminodiphenyl efficiently with a 7 minute difference in retention time.
Solid phase extraction across Waters Sep-Pak C-18 syringe cartridges was considered
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as a means to readily purify the desired diacetylated product. Separations were completed
using manufacturers recommended procedures. Cartridges were conditioned with 500µL
100% acetonitrile, followed by 500 µL 100% 0.1% aqueous acetic acid. Samples were
taken up in 0.1% aqueous acetic acid, 200 µL and injected onto the cartridge. The
cartridge was then washed with 200 µL 0.1% aqueous acetic acid. The product was then
eluted in 3 - 300µL fractions of 40% acetonitrile in 0.1% aqueous acetic acid.
Each fraction was evaluated by LCMS and it was determined that the first two
fractions contained the best ratio of diacetyl- to monoacetyl- diaminodiphenyl sulfide.

Mass Spectrometer Conditions
Thermo Scientific Electron Exactive Orbitrap Mass Spectrometer was run in ESI
positive ion mode flowing ultra pure nitrogen gas. All acquisitions and data analysis were
completed using Thermo Scientific XCalibur Software Version 2.2 SP1.48.
Mass Spectrometer Conditions
Sheath Gas – Nitrogen
30 au
Auxiliary Gas – Nitrogen
15 au
Spary Voltage
4.2 KV
Capillary Temperature
245 Celsius
Capillary Voltage
32.5 V
Tube Lens Voltage
140 V
Skimmer Voltage
28 V
Collision Energy
35 eV
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APPENDIX 2

DIAMINODIPHENYL ANALOGS INHIBIT NMDAR IN XENOPUS OOCYTE

To determine whether the anticonvulsant properties of diaminodiphenyls are a result
of an interaction with N-methyl-D-aspartate receptor, electrophysiology based syudies
were executed in Xenopus oocytes. Mammalian NMDA receptors were expressed in
Xenopus oocytes and functional inhibition of receptor function in response to the agonists
glutamate and glycine was assessed with and without diaminodiphenyl sulfide.
cRNA for the most ubiquitously expressed NMDA channel subunits, NR1A and
NR2B, were injected into Xenopus laevis oocytes. 4-5 days after cRNA injection
electrophysiology was used to characterize NMDA responses. Using the two electrode
voltage clamp configuration ooctyes were clamped at -70mV and perfused with 10mM
glycine and 10uM Glutamate which resulted robust positive inward currents only in
oocytes injected with both channel subunits. Subsequent addition of thiodianiline
inhibited glutamate-dependent current in a concentration-dependent manner. Notably,
NMDA receptor saturation resulted in a maximum inhibition of 60% when compared to
control.
The results of this study confirm the assertion the diaminodiphenyl compounds
modulate the functionof the N-methyl-D-aspartate receptor. Antagonism of this receptor
may be the mechanism by which diaminodiphenyl compounds exert their anticonvulsive
properties.
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